Nitric oxide (NO) is an important signaling molecule that is widely used in the nervous system. With recognition of its roles in synaptic plasticity (long-term potentiation, LTP; long-term depression, LTD) and elucidation of calcium-dependent, NMDAR-mediated activation of neuronal nitric oxide synthase (nNOS), numerous molecular and pharmacological tools have been used to explore the physiology and pathological consequences for nitrergic signaling. In this review, the authors summarize the current understanding of this subtle signaling pathway, discuss the evidence for nitrergic modulation of ion channels and homeostatic modulation of intrinsic excitability, and speculate about the pathological consequences of spillover between different nitrergic compartments in contributing to aberrant signaling in neurodegenerative disorders. Accumulating evidence points to various ion channels and particularly voltage-gated potassium channels as signaling targets, whereby NO mediates activity-dependent control of intrinsic neuronal excitability; such changes could underlie broader mechanisms of synaptic plasticity across neuronal networks. In addition, the inability to constrain NO diffusion suggests that spillover from endothelium (eNOS) and/or immune compartments (iNOS) into the nervous system provides potential pathological sources of NO and where control failure in these other systems could have broader neurological implications. Abnormal NO signaling could therefore contribute to a variety of neurodegenerative pathologies such as stroke/excitotoxicity, Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease.
Abu-Soud HM, Wang J., Rousseau DL, Fukuto JM, Ignarro LJ, Stuehr DJ1995. Neuronal nitric oxide synthase self-inactivates by forming a ferrous-nitrosyl complex during aerobic catalysis. J Biol Chem270:22997-3006.
2.
Ahern GP, Hsu SF, Jackson MB1999. Direct actions of nitric oxide on rat neurohypophysial K+ channels. J Physiol 520 (Pt1):165-76.
3.
Ahern GP, Klyachko VA, Jackson MB2002. cGMP and S-nitrosylation: two routes for modulation of neuronal excitability by NO. Trends Neurosci25:510-7.
4.
Alderton WK, Cooper CE, Knowles RG2001. Nitric oxide synthases: structure, function and inhibition . Biochem J357: 593-615.
5.
Aliev G., Palacios HH, Lipsitt AE, Fischbach K., Lamb BT, Obrenovich ME, and others. 2009. Nitric oxide as an initiator of brain lesions during the development of Alzheimer disease. Neurotox Res16:293-305.
6.
Artinian L., Tornieri K., Zhong L., Baro D., Rehder V.2010. Nitric oxide acts as a volume transmitter to modulate electrical properties of spontaneously firing neurons via apaminsensitive potassium channels. J Neurosci30:1699-711.
7.
Bartho L., Benko R., Holzer-Petsche U., Holzer P., Undi S., Wolf M.2008. Role of extrinsic afferent neurons in gastrointestinal motility. Eur Rev Med Pharmacol Sci12:21-31.
8.
Barthwal MK, Srivastava N., Dikshit M.2001. Role of nitric oxide in a progressive neurodegeneration model of Parkinson’s disease in the rat. Redox Rep6:297-302.
9.
Bauer PM, Fulton D., Boo YC, Sorescu GP, Kemp BE, Jo H., and others. 2003. Compensatory phosphorylation and protein-protein interactions revealed by loss of function and gain of function mutants of multiple serine phosphorylation sites in endothelial nitric-oxide synthase . J Biol Chem278: 14841-9.
10.
Beckman JS, Koppenol WH1996. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol271:C1424-37.
11.
Bennett S., Grant MM, Aldred S.2009. Oxidative stress in vascular dementia and Alzheimer’s disease: a common pathology. J Alzheimers Dis17:245-57.
12.
Biel M., Sautter A., Ludwig A., Hofmann F., Zong X.1998. Cyclic nucleotide-gated channels-mediators of NO:cGMPregulated processes. Naunyn Schmiedebergs Arch Pharmacol358:140-4.
13.
Bo L., Dawson TM, Wesselingh S., Mork S., Choi S., Kong PA, and others. 1994. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol36:778-86.
14.
Bogdan C.2001. Nitric oxide and the immune response. Nat Immunol2:907-16.
15.
Bossy-Wetzel E., Petrilli A., Knott AB2008. Mutant huntingtin and mitochondrial dysfunction. Trends Neurosci31:609-16.
16.
Bossy-Wetzel E., Talantova MV, Lee WD, Scholzke MN, Harrop A., Mathews E., and others. 2004. Crosstalk between nitric oxide and zinc pathways to neuronal cell death involving mitochondrial dysfunction and p38-activated K+ channels. Neuron41:351-65.
17.
Boxall AR, Garthwaite J.1996. Long-term depression in rat cerebellum requires both NO synthase and NO-sensitive guanylyl cyclase. Eur J Neurosci8:2209-12.
18.
Boyle WA III, Parvathaneni LS, Bourlier V., Sauter C., Laubach VE, Cobb JP2000. iNOS gene expression modulates microvascular responsiveness in endotoxin-challenged mice. Circ Res87:E18-24.
19.
Bredt DS, Ferris CD, Snyder SH1992. Nitric oxide synthase regulatory sites: phosphorylation by cyclic AMP-dependent protein kinase, protein kinase C, and calcium/calmodulin protein kinase; identification of flavin and calmodulin binding sites. J Biol Chem267:10976-81.
20.
Brenman JE, Chao DS, Gee SH, McGee AW, Craven SE, Santillano DR, and others. 1996. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell84:757-67.
21.
Burger S., Noack M., Kirazov LP, Kirazov EP, Naydenov CL, Kouznetsova E., and others. 2009. Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain. Int J Dev Neurosci27:517-23.
22.
Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH1992. Nitric oxide: a physiologic mediator of penile erection . Science257:401-3.
23.
Chang YW, Jakobi R., McGinty A., Foschi M., Dunn MJ, Sorokin A.2000. Cyclooxygenase 2 promotes cell survival by stimulation of dynein light chain expression and inhibition of neuronal nitric oxide synthase activity. Mol Cell Biol20:8571-9.
24.
Chaudhury A., He XD, Goyal RKAug 2009. Role of PSD95 in membrane association and catalytic activity of nNOS{alpha} in nitrergic varicosities in mice gut. Am J Physiol Gastrointest Liver Physiol297: G806-G813.
25.
Cheret C., Gervais A., Lelli A., Colin C., Amar L., Ravassard P., and others. 2008. Neurotoxic activation of microglia is promoted by a nox1-dependent NADPH oxidase. J Neurosci28:12039-51.
26.
Cho DH, Nakamura T., Fang J., Cieplak P., Godzik A., Gu Z., and others. 2009. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science324:102-5.
27.
Chung CY, Koprich JB, Endo S., Isacson O.2007. An endogenous serine/threonine protein phosphatase inhibitor, G-substrate, reduces vulnerability in models of Parkinson’s disease . J Neurosci27:8314-23.
28.
Chung KK, Thomas B., Li X., Pletnikova O., Troncoso JC, Marsh L., and others. 2004. S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function. Science304:1328-31.
29.
Closs EI2002. Expression, regulation and function of carrier proteins for cationic amino acids. Curr Opin Nephrol Hyper-tens11:99-107.
30.
Contestabile A.2008. Regulation of transcription factors by nitric oxide in neurons and in neural-derived tumor cells. Prog Neurobiol84:317-28.
31.
Danielson SR, Andersen JK2008. Oxidative and nitrative protein modifications in Parkinson’s disease. Free Radic Biol Med44:1787-94.
32.
de la Torre JC2009. Cerebrovascular and cardiovascular pathology in Alzheimer’s disease. Int Rev Neurobiol84: 35-48.
33.
Dimmeler S., Assmus B., Hermann C., Haendeler J., Zeiher AM1998. Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis. Circ Res83:334-41.
Dudzinski DM, Igarashi J., Greif D., Michel T.2006. The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol46:235-76.
Endo S., Nairn AC, Greengard P., Ito M.2003. Thr123 of rat G-substrate contributes to its action as a protein phosphatase inhibitor. Neurosci Res45:79-89.
38.
Endo S., Shutoh F., Dinh TL, Okamoto T., Ikeda T., Suzuki M., and others. 2009. Dual involvement of G-substrate in motor learning revealed by gene deletion. Proc Natl Acad Sci USA106:3525-30.
39.
Erusalimsky JD, Moncada S.2007. Nitric oxide and mitochondrial signaling: from physiology to pathophysiology. Arterioscler Thromb Vasc Biol27:2524-31.
40.
Erwin PA, Lin AJ, Golan DE, Michel T.2005. Receptor-regulated dynamic S-nitrosylation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem280:19888-94.
41.
Fleming I., Fisslthaler B., Dimmeler S., Kemp BE, Busse R.2001. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res88:E68-75.
42.
Fleming I., Schulz C., Fichtlscherer B., Kemp BE, Fisslthaler B., Busse R.2003. AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets. Thromb Haemost90:863-71.
43.
Flodstrom M., Horwitz MS, Maday A., Balakrishna D., Rodriguez E., Sarvetnick N.2001. A critical role for inducible nitric oxide synthase in host survival following coxsackievirus B4 infection. Virology281:205-15.
44.
Foxton RH, Land JM, Heales SJ2007. Tetrahydrobiopterin availability in Parkinson’s and Alzheimer’s disease; potential pathogenic mechanisms. Neurochem Res32:751-6.
45.
Friebe A., Koesling D.2009. The function of NO-sensitive guanylyl cyclase: what we can learn from genetic mouse models. Nitric Oxide21:149-56.
46.
Fulton D., Ruan L., Sood SG, Li C., Zhang Q., Venema RC2008. Agonist-stimulated endothelial nitric oxide synthase activation and vascular relaxation: role of eNOS phosphorylation at Tyr83. Circ Res102:497-504.
47.
Furchgott RF, Zawadzki JV1980. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature288:373-6.
48.
Gally JA, Montague PR, Reeke GN Jr, Edelman GM1990. The NO hypothesis: possible effects of a short-lived, rapidly diffusible signal in the development and function of the nervous system . Proc Natl Acad Sci USA87:3547-51.
49.
Garthwaite G., Bartus K., Malcolm D., Goodwin D., Kollb-Sielecka M., Dooldeniya C., and others. 2006. Signaling from blood vessels to CNS axons through nitric oxide. J Neurosci26:7730-40.
Gatto EM, Riobo NA, Carreras MC, Chernavsky A., Rubio A., Satz ML, and others. 2000. Overexpression of neutrophil neuronal nitric oxide synthase in Parkinson’s disease. Nitric Oxide4:534-9.
52.
Gillardon F., Krep H., Brinker G., Lenz C., Bottiger B., Hossmann KA1998. Induction of protein inhibitor of neuronal nitric oxide synthase/cytoplasmic dynein light chain following cerebral ischemia. Neuroscience84:81-8.
53.
Gingerich S., Krukoff TL2008. Activation of ERbeta increases levels of phosphorylated nNOS and NO production through a Src/PI3K/Akt-dependent pathway in hypothalamic neurons. Neuropharmacology55:878-85.
54.
Gomez R., Nunez L., Vaquero M., Amoros I., Barana A., de Prada T., and others. 2008. Nitric oxide inhibits Kv4.3 and human cardiac transient outward potassium current (Ito1). Cardiovasc Res80:375-84.
55.
Gonzalez-Forero D., Portillo F., Gomez L., Montero F., Kasparov S., Moreno-Lopez B.2007. Inhibition of resting potassium conductances by long-term activation of the NO/cGMP/protein kinase G pathway: a new mechanism regulating neuronal excitability. J Neurosci27:6302-12.
56.
Gyurko R., Leupen S., Huang PL2002. Deletion of exon 6 of the neuronal nitric oxide synthase gene in mice results in hypogonadism and infertility. Endocrinology143:2767-74.
57.
Hamel E., Nicolakakis N., Aboulkassim T., Ongali B., Tong XK2008. Oxidative stress and cerebrovascular dysfunction in mouse models of Alzheimer’s disease. Exp Physiol93:116-20.
58.
Hantraye P., Brouillet E., Ferrante R., Palfi S., Dolan R., Matthews RT, and others. 1996. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med2:1017-21.
59.
Hardingham N., Fox K.2006. The role of nitric oxide and GluR1 in presynaptic and postsynaptic components of neocortical potentiation. J Neurosci26:7395-404.
60.
Hardingham N., Glazewski S., Pakhotin P., Mizuno K., Chapman PF, Giese KP, and others. 2003. Neocortical long-term potentiation and experience-dependent synaptic plasticity require alpha-calcium/calmodulin-dependent protein kinase II auto-phosphorylation. J Neurosci23:4428-36.
61.
Hartell NA1994. cGMP acts within cerebellar Purkinje cells to produce long term depression via mechanisms involving PKC and PKG. Neuroreport5:833-6.
62.
Hayashi Y., Nishio M., Naito Y., Yokokura H., Nimura Y., Hidaka H., and others. 1999. Regulation of neuronal nitric-oxide synthase by calmodulin kinases. J Biol Chem274:20597-602.
63.
Heales SJ, Bolanos JP, Stewart VC, Brookes PS, Land JM, Clark JB1999. Nitric oxide, mitochondria and neurological disease. Biochim Biophys Acta1410:215-28.
64.
Hensley K., Maidt ML, Yu Z., Sang H., Markesbery WR, Floyd RA1998. Electrochemical analysis of protein nitro-tyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci18:8126-32.
65.
Higashi Y., Noma K., Yoshizumi M., Kihara Y.2009. Endothelial function and oxidative stress in cardiovascular diseases. Circ J73:411-8.
66.
Hodara R., Norris EH, Giasson BI, Mishizen-Eberz AJ, Lynch DR, Lee VM, and others. 2004. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem279:47746-53.
67.
Hollenberg SM, Broussard M., Osman J., Parrillo JE2000. Increased microvascular reactivity and improved mortality in septic mice lacking inducible nitric oxide synthase. Circ Res86:774-8.
68.
Huang PL, Dawson TM, Bredt DS, Snyder SH, Fishman MC1993. Targeted disruption of the neuronal nitric oxide synthase gene. Cell75:1273-86.
69.
Huang Y., Man HY, Sekine-Aizawa Y., Han Y., Juluri K., Luo H., and others. 2005. S-nitrosylation of N-ethylmaleimide sensitive factor mediates surface expression of AMPA receptors. Neuron46:533-40.
70.
Huang Z., Huang PL, Ma J., Meng W., Ayata C., Fishman MC, and others. 1996. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab16:981-7.
71.
Hunot S., Boissiere F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., and others. 1996. Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease. Neuroscience72:355-63.
72.
Hurt KJ, Musicki B., Palese MA, Crone JK, Becker RE, Moriarity JL, and others. 2002. Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci USA99:4061-6.
73.
Ihara H., Kuwamura M., Atsuta M., Nihonmatsu I., Okada T., Mukamoto M., and others. 2006. Expression of neuronal nitric oxide synthase variant, nNOS-mu, in rat brain. Nitric Oxide15:13-9.
74.
Jacoby S., Sims RE, Hartell NA2001. Nitric oxide is required for the induction and heterosynaptic spread of long-term potentiation in rat cerebellar slices. J Physiol535:825-39.
75.
Jaffrey SR, Snowman AM, Eliasson MJ, Cohen NA, Snyder SH1998. CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95. Neuron20:115-24.
76.
Jaffrey SR, Snyder SH1996. PIN: an associated protein inhibitor of neuronal nitric oxide synthase. Science274:774-7.
77.
Jeong Y., Won J., Yim J.1998. Cloning and structure of a rabbit protein inhibitor of neuronal nitric oxide synthase (PIN) gene and its pseudogene. Gene214:67-75.
78.
Joy S., Siow RC, Rowlands DJ, Becker M., Wyatt AW, Aaronson PI, and others. 2006. The isoflavone Equol mediates rapid vascular relaxation: Ca2+-independent activation of endothelial nitric-oxide synthase/Hsp90 involving ERK1/2 and Akt phosphorylation in human endothelial cells. J Biol Chem281:27335-45.
79.
Kang Y., Dempo Y., Ohashi A., Saito M., Toyoda H., Sato H., and others. 2007. Nitric oxide activates leak K+ currents in the presumed cholinergic neuron of basal forebrain. J Neurophysiol98:3397-410.
80.
Kawano T., Zoga V., Kimura M., Liang MY, Wu HE, Gemes G., and others. 2009. Nitric oxide activates ATP-sensitive potassium channels in mammalian sensory neurons: action by direct S-nitrosylation . Mol Pain5:12.
81.
Keilhoff G., Fansa H., Wolf G.2004. Neuronal NOS deficiency promotes apoptotic cell death of spinal cord neurons after peripheral nerve transection. Nitric Oxide10:101-11.
82.
Kerchner GA, Nicoll RA2008. Silent synapses and the emergence of a postsynaptic mechanism for LTP. Nat Rev Neurosci9:813-25.
83.
Keynes RG, Griffiths CH, Hall C., Garthwaite J.2005. Nitric oxide consumption through lipid peroxidation in brain cell suspensions and homogenates. Biochem J387:685-94.
84.
Kleppisch T.2009. Phosphodiesterases in the central nervous system. Handb Exp Pharmacol191:71-92.
85.
Knoch ME, Hartnett KA, Hara H., Kandler K., Aizenman E.2008. Microglia induce neurotoxicity via intraneuronal Zn2+ release and a K+ current surge. Glia56:89-96.
86.
Knott AB, Bossy-Wetzel E.2008. Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration. Ann N Y Acad Sci1147:283-92.
87.
Knott AB, Bossy-Wetzel E.2009. Nitric oxide in health and disease of the nervous system . Antioxid Redox Signal11: 541-54.
88.
Knott AB, Perkins G., Schwarzenbacher R., Bossy-Wetzel E.2008. Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci9:505-18.
89.
Komeima K., Hayashi Y., Naito Y., Watanabe Y.2000. Inhibition of neuronal nitric-oxide synthase by calcium/calmodulin-dependent protein kinase IIalpha through Ser847 phosphorylation in NG108-15 neuronal cells. J Biol Chem275:28139-43.
90.
Korneev SA, Straub V., Kemenes I., Korneeva EI, Ott SR, Benjamin PR, and others. 2005. Timed and targeted differential regulation of nitric oxide synthase (NOS) and anti-NOS genes by reward conditioning leading to long-term memory formation. J Neurosci25:1188-92.
91.
Kroncke KD, Fehsel K., Schmidt T., Zenke FT, Dasting I., Wesener JR, and others. 1994. Nitric oxide destroys zinc-sulfur clusters inducing zinc release from metallothionein and inhibition of the zinc finger-type yeast transcription activator LAC9. Biochem Biophys Res Commun200:1105-10.
92.
Kuiper MA, Visser JJ, Bergmans PL, Scheltens P., Wolters EC1994. Decreased cerebrospinal fluid nitrate levels in Parkinson’s disease, Alzheimer’s disease and multiple system atrophy patients. J Neurol Sci121:46-9.
93.
Kurauchi Y., Hisatsune A., Isohama Y., Katsuki H.2009. Nitric oxide-cyclic GMP signaling pathway limits inflammatory degeneration of midbrain dopaminergic neurons: cell type-specific regulation of heme oxygenase-1 expression. Neuroscience158:856-66.
94.
Langnaese K., Richter K., Smalla KH, Krauss M., Thomas U., Wolf G., and others. 2007. Splice-isoform specific immunolocalization of neuronal nitric oxide synthase in mouse and rat brain reveals that the PDZ-complex-building nNOSalpha beta-finger is largely exposed to antibodies . Dev Neurobiol67:422-37.
95.
Lee MY, Griendling KK2008. Redox signaling, vascular function, and hypertension. Antioxid Redox Signal10:1045-59.
96.
Lei S., Jackson MF, Jia Z., Roder J., Bai D., Orser BA, and others. 2000. Cyclic GMP-dependent feedback inhibition of AMPA receptors is independent of PKG. Nat Neurosci3:559-65.
97.
Lipton SA, Choi YB, Takahashi H., Zhang D., Li W., Godzik A., and others. 2002. Cysteine regulation of protein function- as exemplified by NMDA-receptor modulation. Trends Neurosci25:474-80.
98.
Liu J., Garcia-Cardena G., Sessa WC1995. Biosynthesis and palmitoylation of endothelial nitric oxide synthase: mutagenesis of palmitoylation sites, cysteines-15 and/or -26, argues against depalmitoylation-induced translocation of the enzyme. Biochemistry34:12333-40.
99.
Malenka RC, Bear MF2004. LTP and LTD: an embarrassment of riches. Neuron44:5-21.
100.
Malinow R., Malenka RC2002. AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci25:103-26.
101.
Manczak M., Anekonda TS, Henson E., Park BS, Quinn J., Reddy PH2006. Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet15:1437-49.
102.
Mann GE, Yudilevich DL, Sobrevia L.2003. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev83:183-252.
103.
Marlatt MW, Lucassen PJ, Perry G., Smith MA, Zhu X.2008. Alzheimer’s disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies. J Alzheimers Dis15: 199-210.
104.
Michel JB, Feron O., Sase K., Prabhakar P., Michel T.1997. Caveolin versus calmodulin: counterbalancing allosteric modulators of endothelial nitric oxide synthase. J Biol Chem272:25907-12.
105.
Michel T.1999. Targeting and translocation of endothelial nitric oxide synthase. Braz J Med Biol Res32:1361-6.
106.
Michell BJ, Harris MB, Chen ZP, Ju H., Venema VJ, Blackstone MA, and others. 2002. Identification of regulatory sites of phosphorylation of the bovine endothelial nitric-oxide synthase at serine 617 and serine 635. J Biol Chem277:42344-51.
107.
Miller RL, James-Kracke M., Sun GY, Sun AY2009. Oxidative and inflammatory pathways in Parkinson’s disease. Neurochem Res34:55-65.
108.
Mitchell DA, Erwin PA, Michel T., Marletta MA2005. Snitrosation and regulation of inducible nitric oxide synthase. Biochemistry44:4636-47.
Moreno H., Vega-Saenz de Miera E., Nadal MS, Amarillo Y., Rudy B.2001. Modulation of Kv3 potassium channels expressed in CHO cells by a nitric oxide-activated phosphatase. J Physiol530:345-58.
111.
Mount PF, Fraser SA, Watanabe Y., Lane N., Katsis F., Chen ZP, and others. 2006. Phosphorylation of neuronal and endothelial nitric oxide synthase in the kidney with high and low salt diets. Nephron Physiol102:p36-50.
112.
Mount PF, Kemp BE, Power DA2007. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol42:271-9.
113.
Mustafa AK, Gadalla MM, Snyder SH2009. Signaling by gasotransmitters. Sci Signal2:re2.
114.
Nakagomi S., Barsoum MJ, Bossy-Wetzel E., Sutterlin C., Malhotra V., Lipton SA2008. A Golgi fragmentation pathway in neurodegeneration. Neurobiol Dis29:221-31.
115.
Nakane M., Mitchell J., Forstermann U., Murad F.1991. Phosphorylation by calcium calmodulin-dependent protein kinase II and protein kinase C modulates the activity of nitric oxide synthase . Biochem Biophys Res Commun180:1396-402.
116.
Nanhoe-Mahabier W., de Laat KF, Visser JE, Zijlmans J., de Leeuw FE, Bloem BR2009. Parkinson disease and comorbid cerebrovascular disease . Nat Rev Neurol5:533-41.
117.
Niwa K., Porter VA, Kazama K., Cornfield D., Carlson GA, Iadecola C.2001. A beta-peptides enhance vasoconstriction in cerebral circulation . Am J Physiol Heart Circ Physiol281:H2417-24.
118.
Nunez L., Vaquero M., Gomez R., Caballero R., Mateos-Caceres P., Macaya C., and others. 2006. Nitric oxide blocks hKv1.5 channels by S-nitrosylation and by a cyclic GMP-dependent mechanism. Cardiovasc Res72:80-9.
119.
O’Dell TJ, Huang PL, Dawson TM, Dinerman JL, Snyder SH, Kandel ER, and others. 1994. Endothelial NOS and the blockade of LTP by NOS inhibitors in mice lacking neuronal NOS. Science265:542-6.
120.
Ogasawara H., Doi T., Doya K., Kawato M.2007. Nitric oxide regulates input specificity of long-term depression and context dependence of cerebellar learning. PLoS Comput Biol3:e179.
121.
Ortiz PA, Garvin JL2003. Cardiovascular and renal control in NOS-deficient mouse models. Am J Physiol Regul Integr Comp Physiol284:R628-38.
122.
Pan J., Burgher KL, Szczepanik AM, Ringheim GE1996. Tyrosine phosphorylation of inducible nitric oxide synthase: implications for potential post-translational regulation. Biochem J314:889-94.
123.
Phillips KG, Hardingham NR, Fox K.2008. Postsynaptic action potentials are required for nitric-oxide-dependent long-term potentiation in CA1 neurons of adult GluR1 knock-out and wild-type mice. J Neurosci28:14031-41.
124.
Qiu DL, Knopfel T.2007. An NMDA receptor/nitric oxide cascade in presynaptic parallel fiber-Purkinje neuron long-term potentiation. J Neurosci27:3408-15.
125.
Queen LR, Ji Y., Xu B., Young L., Yao K., Wyatt AW, and others. 2006. Mechanisms underlying beta2-adrenoceptor-mediated nitric oxide generation by human umbilical vein endothelial cells. J Physiol576:585-94.
126.
Rameau GA, Chiu LY, Ziff EB2004. Bidirectional regulation of neuronal nitric-oxide synthase phosphorylation at serine 847 by the N-methyl-D-aspartate receptor. J Biol Chem279: 14307-14.
127.
Rameau GA, Tukey DS, Garcin-Hosfield ED, Titcombe RF, Misra C., Khatri L., and others. 2007. Biphasic coupling of neuronal nitric oxide synthase phosphorylation to the NMDA receptor regulates AMPA receptor trafficking and neuronal cell death. J Neurosci27:3445-55.
128.
Regehr WG, Carey MR, Best AR2009. Activity-dependent regulation of synapses by retrograde messengers. Neuron63:154-70.
129.
Reynolds MR, Berry RW, Binder LI2005. Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer’s disease . Biochemistry44:1690-700.
130.
Ribeiro M., Straub VA, Schofield M., Picot J., Benjamin PR, O’Shea M., and others. 2008. Characterization of NO-sensitive guanylyl cyclase: expression in an identified interneuron involved in NO-cGMP-dependent memory formation. Eur J Neurosci28:1157-65.
131.
Rogers NE, Ignarro LJ1992. Constitutive nitric oxide synthase from cerebellum is reversibly inhibited by nitric oxide formed from L-arginine. Biochem Biophys Res Commun189:242-9.
132.
Rotmann A., Simon A., Martine U., Habermeier A., Closs EI2007. Activation of classical protein kinase C decreases transport via systems y+ and y+L. Am J Physiol Cell Physiol292: C2259-68.
133.
Roy B., Garthwaite J.2006. Nitric oxide activation of guanylyl cyclase in cells revisited . Proc Natl Acad Sci USA103: 12185-90.
134.
Ryu JK, Cho T., Choi HB, Wang YT, McLarnon JG2009. Microglial VEGF receptor response is an integral chemotactic component in Alzheimer’s disease pathology. J Neurosci29:3-13.
135.
Sanders KM, Koh SD2006. Two-pore-domain potassium channels in smooth muscles: new components of myogenic regulation. J Physiol570:37-43.
136.
Schapira AH, Cooper JM, Dexter D., Jenner P., Clark JB, Marsden CD1989. Mitochondrial complex I deficiency in Parkinson’s disease. Lancet1:1269.
Serulle Y., Arancio O., Ziff EB2008. A role for cGMP-dependent protein kinase II in AMPA receptor trafficking and synaptic plasticity. Channels2:230-2.
139.
Sessa WC2004. eNOS at a glance. J Cell Sci117:2427-9.
140.
Shaul PW, Smart EJ, Robinson LJ, German Z., Yuhanna IS, Ying Y., and others. 1996. Acylation targets emdothelial nitric-oxide synthase to plasmalemmal caveolae. J Biol Chem271:6518-22.
141.
Shibuki K., Okada D.1991. Endogenous nitric oxide release required for long-term synaptic depression in the cerebellum. Nature349:326-8.
142.
Shin JH, Linden DJ2005. An NMDA receptor/nitric oxide cascade is involved in cerebellar LTD but is not localized to the parallel fiber terminal. J Neurophysiol94:4281-9.
143.
Sims NR, Nilsson M., Muyderman H.2004. Mitochondrial glutathione: a modulator of brain cell death . J Bioenerg Biomembr36:329-33.
144.
Singh S., Das T., Ravindran A., Chaturvedi RK, Shukla Y., Agarwal AK, and others. 2005. Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson’s disease. Redox Rep10:103-9.
145.
Son H., Hawkins RD, Martin K., Kiebler M., Huang PL, Fishman MC, and others. 1996. Long-term potentiation is reduced in mice that are doubly mutant in endothelial and neuronal nitric oxide synthase . Cell87:1015-23.
146.
Song I., Huganir RL2002. Regulation of AMPA receptors during synaptic plasticity . Trends Neurosci25:578-88.
147.
Song T., Hatano N., Horii M., Tokumitsu H., Yamaguchi F., Tokuda M., and others. 2004. Calcium/calmodulin-dependent protein kinase I inhibits neuronal nitric-oxide synthase activity through serine 741 phosphorylation. FEBS Lett570: 133-7.
148.
Song T., Hatano N., Kume K., Sugimoto K., Yamaguchi F., Tokuda M., and others. 2005. Inhibition of neuronal nitric-oxide synthase by phosphorylation at Threonine1296 in NG108-15 neuronal cells. FEBS Lett579:5658-62.
Steinert JR, Kopp-Scheinpflug C., Baker C., Challiss RA, Mistry R., Haustein MD, and others. 2008. Nitric oxide is a volume transmitter regulating postsynaptic excitability at a glutamatergic synapse. Neuron60:642-56.
151.
Steinert JR, Wyatt AW, Jacob R., Mann GE2009. Redox modulation of Ca2+ signaling in human endothelial and smooth muscle cells in pre-eclampsia. Antioxid Redox Signal11:1149-63.
152.
Sultana R., Perluigi M., Butterfield DA2009. Oxidatively modified proteins in Alzheimer’s disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol118:131-50.
153.
Sultana R., Perluigi M., Newman SF, Pierce WM, Cini C., Coccia R., and others. 2010. Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer’s disease . Antioxid Redox Signal12: 327-36.
154.
Sultana R., Poon HF, Cai J., Pierce WM, Merchant M., Klein JB, and others. 2006. Identification of nitrated proteins in Alzheimer’s disease brain using a redox proteomics approach. Neurobiol Dis22:76-87.
155.
Takahashi H.2002. Pathology of neurodegenerative diseases: with special reference to Parkinson’s disease and amyotrophic lateral sclerosis. Rinsho Shinkeigaku42:1085-7.
156.
Takahashi H., Shin Y., Cho SJ, Zago WM, Nakamura T., Gu Z., and others. 2007. Hypoxia enhances S-nitrosylation-mediated NMDA receptor inhibition via a thiol oxygen sensor motif. Neuron53:53-64.
157.
Tansey EP, Chow A., Rudy B., McBain CJ2002. Developmental expression of potassium-channel subunit Kv3.2 within subpopulations of mouse hippocampal inhibitory interneurons. Hippocampus12:137-48.
158.
Taqatqeh F., Mergia E., Neitz A., Eysel UT, Koesling D., Mittmann T.2009. More than a retrograde messenger: nitric oxide needs two cGMP pathways to induce hippocampal long-term potentiation. J Neurosci29:9344-50.
159.
Tarkowski E., Issa R., Sjogren M., Wallin A., Blennow K., Tarkowski A., and others. 2002. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer’s disease and vascular dementia. Neurobiol Aging23:237-43.
160.
Toda N., Herman AG2005. Gastrointestinal function regulation by nitrergic efferent nerves. Pharmacol Rev57: 315-38.
161.
Townsend KP, Obregon D., Quadros A., Patel N., Volmar C., Paris D., and others. 2002. Proinflammatory and vasoactive effects of Abeta in the cerebrovasculature. Ann N Y Acad Sci977:65-76.
162.
Tran MH, Yamada K., Nakajima A., Mizuno M., He J., Kamei H., and others. 2003. Tyrosine nitration of a synaptic protein synaptophysin contributes to amyloid beta-peptide-induced cholinergic dysfunction . Mol Psychiatry8:407-12.
163.
Tsutsui M., Shimokawa H., Morishita T., Nakashima Y., Yanagihara N.2006. Development of genetically engineered mice lacking all three nitric oxide synthases. J Pharmacol Sci102:147-54.
164.
Wallace MN, Geddes JG, Farquhar DA, Masson MR1997. Nitric oxide synthase in reactive astrocytes adjacent to beta-amyloid plaques. Exp Neurol144:266-72.
165.
Wang X., Zhao Q., Matta R., Meng X., Liu X., Liu CG, and others. 2009. Inducible nitric-oxide synthase expression is regulated by mitogen-activated protein kinase phosphatase-1. J Biol Chem284:27123-34.
166.
Wood J., Garthwaite J.1994. Models of the diffusional spread of nitric oxide: implications for neural nitric oxide signalling and its pharmacological properties. Neuropharmacology33:1235-44.
167.
Xia Y., Dawson VL, Dawson TM, Snyder SH, Zweier JL1996. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA93:6770-4.
168.
Yang Q., Chen SR, Li DP, Pan HL2007. Kv1.1/1.2 channels are downstream effectors of nitric oxide on synaptic GABA release to preautonomic neurons in the paraventricular nucleus. Neuroscience149:315-27.
169.
Yang SP, Bae DG, Kang HJ, Gwag BJ, Gho YS, Chae CB2004. Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer’s disease . Neurobiol Aging25:283-90.
170.
Yao D., Gu Z., Nakamura T., Shi ZQ, Ma Y., Gaston B., and others. 2004. Nitrosative stress linked to sporadic Parkinson’s disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci USA101: 10810-4.
171.
Yokoyama H., Yano R., Aoki E., Kato H., Araki T.2008. Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice. Metab Brain Dis23:335-49.
172.
Yuan H., Gerencser AA, Liot G., Lipton SA, Ellisman M., Perkins GA, and others. 2007. Mitochondrial fission is an upstream and required event for bax foci formation in response to nitric oxide in cortical neurons. Cell Death Differ14:462-71.
173.
Zhang Z., Klyachko V., Jackson MB2007. Blockade of phosphodiesterase type 5 enhances rat neurohypophysial excitability and electrically evoked oxytocin release. J Physiol584:137-47.
174.
Zuliani G., Cavalieri M., Galvani M., Passaro A., Munari MR, Bosi C., and others. 2008. Markers of endothelial dysfunction in older subjects with late onset Alzheimer’s disease or vascular dementia . J Neurol Sci272:164-70.
